Lucid Diagnostics Inc. (LUCD)
NCM · Medical Devices
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Peers in Medical Devices
All in industry →Abbott Laboratories
Stryker Corporation
Medtronic plc
Boston Scientific Corporation
Edwards Lifesciences Corporation
GE HealthCare Technologies Inc.
Koninklijke Philips N.V.
DexCom, Inc.
STERIS plc
Zimmer Biomet Holdings, Inc.
Recent press releases
Lucid Diagnostics Inc. has not issued a press release in this window.
SEC filings
All filings →Lucid Diagnostics Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Lucid Diagnostics Inc. has no reported insider trades in the last 90 days.